Randomized trial demonstrates improved effectiveness and safety in HIV-1 treatment using dolutegravir-based regimen, suggesting a better option for patients.
Dolutegravir plus abacavir-lamivudine had a better safety profile and was more effective through 48 weeks than the regimen with efavirenz-tenofovir DF-emtricitabine. (Funded by ViiV Healthcare; SINGLE ClinicalTrials.gov number, NCT01263015 .).
No takes yet. Share an insight, caveat, or question.
Walmsley et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: